The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- Immune duo safely targets hard-to-treat gynecological cancers
- Toward a cure for multiple myeloma within a decade
- FDA approves Tecvayli, Darzalex Faspro in combo for hard-to-treat myeloma
- Small molecule screening identifies cytotoxic endoplasmic reticulum-associated degradation inhibitors in multiple myeloma
- AML treatment combo helps most trial patients reach remission
- The [(18)F]FDG PET/CT for prognostic stratification in multiple myeloma: A systematic review and meta-analysis
- (no title)
- Teclistamab-daratumumab snag FDA approval in multiple myeloma
- Experimental therapy outperforms approved treatment in PNET trial
- (no title)